The management of phobic disorders using clomipramine (Anafranil).
The problem of phobic anxiety is viewed in the context of the entire area of mental illness and of its epidemiology in the general population. The importance of the diagnosis of depression in phobic patients and its simultaneous treatment is emphasized. Psychotherapeutic and psychopharmacological methods are discussed and some results of recent trials of clomipramine (Anafranil) are reported. The author concludes that for the successful outcome of treatment an eclectic approach must be considered. The combination of behavioural techniques of desensitization along a hierarchy of anxiety-provoking situations, together with psychotherapeutic support and the simultaneous exhibition of the more specific antidepressant and antiphobic preparation clomipramine would offer the best hope of symptom relief.
D001521:Behavior Therapy; D002997:Clomipramine / Q000627:therapeutic use*; D003984:Dibenzazepines / Q000627:therapeutic use*; D006801:Humans; D010698:Phobic Disorders / Q000188:drug therapy* / Q000628:therapy; D012064:Relaxation Therapy
D003984:Dibenzazepines; D002997:Clomipramine